Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug;44(8):3139-3151.
doi: 10.1007/s10067-025-07557-y. Epub 2025 Jul 2.

Stem cell therapy in systemic sclerosis

Lazaros I Sakkas  1 , Theodora Simopoulou  2 , Ioannis Alexiou  3 , Christos Liaskos  4 , Ian C Chikanza  5   6
Affiliations
Review

Stem cell therapy in systemic sclerosis

Lazaros I Sakkas et al. Clin Rheumatol. 2025 Aug.

Abstract

Systemic sclerosis is a complex autoimmune disease with widespread fibrosis in skin and internal organs, microvasculopathy, and autoantibodies. The disease causes ischemic changes and leads to impairment of internal organs with reduced quality of life and life expectancy. The pathogenesis is not clearly known but involves adaptive and innate immune cells which infiltrate skin lesions mostly early in the disease process. Current treatment is based on immunosuppressives, but there is a significant unmet therapeutic need, and a new therapeutic approach is required. Autologous haematopoietic stem cell transplantation appears to be an effective therapeutic option for SSc but requires standardization to reduce transplant-related mortality and post-transplant adverse effects. Mesenchymal stem cells (MSCs), exerting immunosuppressive, antifibrotic, and angiogenic actions, appear to be a promising therapeutic option but require further refinement. MSC-derived microvesicles retain MSC functions and circumvent some of the MSC challenges and thus may provide a more favorable therapeutic approach. Key Points • There are unmet therapeutic needs for systemic sclerosis. • Autologous haematopoietic stem cell transplantation is an effective therapeutic option but needs standarization. • Mesenchymal stem cells are a promising therapeutic option but requires refinement.

Keywords: Adipose-derived mesenchymal stem cells; Bone marrow-derived mesenchymal stem cells; Haematopoietic stem cells; Mesenchymal stem cells; Stem cell transplantation.

PubMed Disclaimer

Conflict of interest statement

Compliance with ethical standards. Disclosures: None.

Figures

Fig. 1
Fig. 1
Flowchart of autologous haematopoietic stem cell(AHSC) transplantation. CyP: cyclophosphamide; GCSF: granulocyte colony stimulating factor
See this image and copyright information in PMC

References

    1. Volkman ER, Andreasson K, Smith V (2023) Systemic sclerosis. Lancet 401(10373):304–318. - PMC - PubMed
    1. LI Sakkas IC Chikanza CD Platsoucas 2006 Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis Nat Clin Pract Rheumatol 2(12):679 685. 10.1038/ncprheum0346 - PubMed
    1. Sakkas LI, Katsiari CG, Daoussis D, Bogdanos DP (2023) The role of B cells in the pathogenesis of systemic sclerosis: an update. Rheumatology (Oxford) 62(5):1780–1786. 10.1093/rheumatology/keac578 - PubMed
    1. R Lande EY Lee R Palazzo 2019 CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-Α production in systemic sclerosis Nat Commun 10:1731.10.1038/s41467-019-09683-z - PMC - PubMed
    1. Skaug B, Lyons MA, Swindell WR, Salazar GA, Wu M, Tran TM, Charles J, Vershel CP, Mayes MD, Assassi S (2022) Large-scale analysis of longitudinal skin gene expression in systemic sclerosis reveals relationships of immune cell and fibroblast activity with skin thickness and a trend towards normalisation over time. Ann Rheum Dis 81(4):516–523. 10.1136/annrheumdis-2021-221352 - PMC - PubMed

MeSH terms

LinkOut - more resources